Profile: Capstone Therapeutics develops a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. We focus on development and commercialization of two product platforms that include AZX100 and Chrysalin®. AZX100 is a novel synthetic 24-amino acid peptide, one of a new class of compounds in the field of smooth muscle relaxation and fibrosis. Based on its demonstrated effects in pre-clinical models and safety in Phase 1 clinical trials, AZX100 is evaluated for commercially significant medical applications such as the treatment of pulmonary disease, the prevention of hypertrophic and keloid scarring and intimal hyperplasia. Chrysalin,(rusalatide acetate or TP508) is a novel synthetic 23-amino acid peptide,which has been proven in multiple pre-clinical and clinical models to stimulate cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues.

The company has revenues of USD 50-100 Million, has ~510 employees. NASDAQ:OLGC (SEC Filings)